Dinaciclib is a pan−CDKi with nanomolar potency towards CDK1, CDK2, CDK5, and CDK9 [35] and potent activity against a range of human cancer cell lines with promising results in preclinical safety and pharmacokinetic studies [35]. This evidence concerns the gene CDK5 and cancer.